pyrimidinones and Lymphatic-Abnormalities

pyrimidinones has been researched along with Lymphatic-Abnormalities* in 1 studies

Other Studies

1 other study(ies) available for pyrimidinones and Lymphatic-Abnormalities

ArticleYear
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
    Nature medicine, 2019, Volume: 25, Issue:7

    Topics: Adult; Animals; Child; Exome Sequencing; Female; HEK293 Cells; Humans; Lymphatic Abnormalities; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins A-raf; Pyridones; Pyrimidinones; Zebrafish

2019